Geron Corp Stock Price, News & Analysis

Geron Corporation (Nasdaq: GERN) has granted a non-statutory stock option to purchase 70,000 shares of common stock to a new employee as an induction measure. This option was granted on June 15, 2022, with an exercise price of $1.30 per share, equal to the stock's closing price on that date. The option vests over four years, starting with 12.5% after six months, subject to continued employment. Geron, focused on developing a telomerase inhibitor for hematologic malignancies, is conducting two Phase 3 trials: IMerge and IMpactMF.

Geron Corporation (NASDAQ: GERN) has appointed Faye Feller, M.D., as Executive Vice President and Chief Medical Officer effective July 9, 2022. She succeeds Dr. Aleksandra Rizo, who will move to a consulting role after leading imetelstat's development. Dr. Feller has significant experience with imetelstat, having been involved in its development at Geron and previously at Janssen. The company anticipates top-line results from the IMerge Phase 3 trial in early January 2023, which could lead to a New Drug Application submission for imetelstat in lower risk myelodysplastic syndromes.

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for an aggregate of 327,400 shares to new hires, effective May 18, 2022. The options have an exercise price of $1.30 per share and a 10-year term, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4). Geron is engaged in developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge and IMpactMF, targeting hematologic malignancies.

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that CEO John A. Scarlett will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation starts on May 24, 2022, at 7 a.m. ET. A webcast will be accessible in the Investor Relations section of Geron's website, with an archive available for 30 days after the event. Geron is advancing its lead candidate, imetelstat, through two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) reported its Q1 2022 financial results, highlighting a net loss of $30.1 million, unchanged EPS at $0.09, and revenues of $123,000. The company has $178 million in cash and marketable securities and completed a public offering in April, raising approximately $70 million. The company anticipates sufficient resources to support operations through the end of 2023. Key milestones include the upcoming Phase 3 IMerge trial results and the initiation of the IMproveMF study, aiming to enhance treatment options for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) will release its first quarter 2022 financial results on May 9, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET the same day to discuss the results and recent developments. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. The press release and webcast details are accessible on their website.

Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options for 505,800 shares of common stock to newly hired employees as an inducement for employment. The options, granted on April 20, 2022, have an exercise price of $1.47, matching the stock's closing price on that date. They have a 10-year term and will vest over four years, beginning with a 12.5% vesting at six months. Geron is focused on developing imetelstat, a telomerase inhibitor, currently in two Phase 3 clinical trials for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) announced that CEO John A. Scarlett will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:45 p.m. ET. The presentation can be accessed via a live webcast on Geron's Investor Relations website, with an archived replay available for 30 days afterward.

Geron is focused on the development of imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (NASDAQ: GERN) has successfully closed an underwritten public offering, raising approximately $70 million by selling 53,333,334 shares of common stock and 18,095,238 pre-funded warrants. Each share was priced at $1.05 with accompanying warrants. The net proceeds will be used to support regulatory filings for imetelstat in myelodysplastic syndromes and to fund ongoing clinical trials for myelofibrosis and other indications. This financing positions Geron for further advancements in its pipeline.